SAN DIEGO and SUZHOU, China, Nov 11 (Bernama-GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced clinical data from phase 1b/2 studies of its anti-CTLA-4 antibody candidate, ADG116, in two poster presentations at the Society forImmunotherapy of Cancer’s (SITC) Annual Meeting taking place in Boston.
One poster titled “A Phase 1b/2 Study of a Novel Anti-CTLA-4 NEObody™ ADG116 Monotherapy and in Combination with Toripalimab (Tori; Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors” reviewed data from an open label, phase 1b/2 dose escalation and dose expansion trial evaluating ADG116 as monotherapy and in combination with toripalimab in heavily pre-treated patients with advanced metastatic solid tumors.
